Select committee: Science and Technology Committee

Engineering biology

Closed Opened 28 Mar 2024 Closed 28 Apr 2025
Inquiry scope (the committee's words)
The House of Lords Science and Technology Committee is conducting an inquiry into engineering biology. The committee will explore engineering biology’s potential, particularly in delivering UK economic growth through commercialisation and for improvements to public services; which areas of engineering biology the UK is well placed to exploit and where additional support may be needed; and the ethical, regulatory and safety implications of rapid developments in the field. The committee has issued a call for written evidence and will be taking oral evidence from April 2024. Read the key points in our report summary

Where it stands

The inquiry is closed, opened 28 March 2024.

The committee has published 1 report, most recently 1st Report - Don’t fail to scale: seizing the opportunity of engineering biology on 14 January 2025.

The government's response

Minister of State for Science, Research and Innovation response to Don’t fail to scale: seizing the opportunity of engineering biology

Published 17 March 2025. The deadline was 14 March 2025.

Summary written by Accountability Index from the government's response. It is not the government's own words.

The government notes the Committee's conclusions and recommendations, agrees that engineering biology offers significant potential for economic growth, and sets out existing and planned actions, while recognising "there is more to do".

  • It agrees on the sector's potential and says it recognises "the need for urgency" to strengthen the UK's position, with the ability of companies to scale up in the UK described as central.
  • On regulation, it cites the Regulatory Innovation Agency, with engineering biology as one of its four early priority areas, and says the second round of the EB Sandbox Fund will open in April 2025.
  • On infrastructure for scale-up, it is "working closely with the EB Advisory Panel to understand how different models for infrastructure have strengths and weaknesses"; no firm infrastructure commitment is stated.
  • On funding, it points to the Mansion House Compact, reforms to the British Business Bank, and the National Wealth Fund with £5.8 billion of additional funding, raising its total capitalisation to £27.8 billion.

Read the government's response ↗ Report an error

Government response to Don’t fail to scale: seizing the opportunity of engineering biology

Published 17 March 2025.

Summary written by Accountability Index from the government's response. It is not the government's own words.

The government welcomes the Lords report, says it agrees that engineering biology offers 'significant economic growth and impact', and accepts or agrees with most recommendations, with some qualifications and one it is 'not currently in a position to accept'.

  • On the Industrial Strategy, it says it "will introduce a new Industrial Strategy in Spring 2025" and, on a national sector champion, that it "will work internally and with the sector to explore the feasibility" of one.
  • On the £2 billion funding target, it does not recommit to it; it says further details of allocation "will be announced in due course", with departmental settlements announced in June.
  • On immigration health surcharge and visa costs, it states it "is not currently in a position to accept this recommendation", citing the principle that those who use the immigration system should contribute to its cost.
  • On DNA synthesis screening, it "will consider putting the guidance on a statutory footing in the future if we deem it necessary and appropriate", stating that moving too quickly risks damaging the sector.

Read the government's response ↗ Report an error

Oral evidence sessions

6 sessions

On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.

Date Session and witnesses Source
15 Oct 2024
Oral evidence session
Alexandra Jones · Department for Science, Innovation and Technology, Dr Isabel Webb · Department for Science, Innovation and Technology, Lord Patrick Vallance · DSIT
View ↗
21 May 2024
Oral evidence session
Charles Hall · Peel Hunt, Dr Hendrik Waegeman · Bio Base Europe Pilot Plant, Dr Mary Maxon · BioFutures, Schmidt Sciences, Dr Peter Williams · INEOS Group Ltd, Fiona Mischel · SynBioBeta, Greg Archer · LanzaTech UK
View ↗
14 May 2024
Oral evidence session
Dr Clive Dix · C4X Discovery, Dr Sara Holland · Potter Clarkson, Graeme Cruickshank · Centre for Process Innovation, Professor Nick Talbot · The Sainsbury Laboratory, The Rt Hon Lord Willetts · SynBioVen
View ↗
7 May 2024
Oral evidence session
Dan Osgood · Department for Energy Security and Net Zero, Dr Michael Adeogun · National Physical Laboratory, Justin Tomlinson MP · Department for Energy Security and Net Zero, Professor Isabel Oliver · UK Health Security Agency, Professor Robin May · Food Standards Agency
View ↗
23 Apr 2024
Oral evidence session
Dr Jim Ajioka · Colorifix, Dr Martin Turner · Bioindustry Association, Mark Bustard · Industrial Biotechnology Innovation Centre, Rosemary Dokos · Oxford Nanopore Technologies, Will Milligan · Extracellular
View ↗
16 Apr 2024
Oral evidence session
Dr Carolina Grandellis · Earlham Institute, Dr Lucia Marucci · University of Bristol, Professor Paul Freemont · Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE), Professor Susan Rosser · Edinburgh Genome Foundry, Professor Tom Ellis · Imperial College London
View ↗

Who gave evidence

29 witnesses

On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.

WitnessOrganisationSessions
Alexandra Jones · Director General for Science Department for Science, Innovation and Technology 1
Charles Hall · Head of Research Peel Hunt 1
Dan Osgood · Director of Energy Markets and Analysis Department for Energy Security and Net Zero 1
Dr Carolina Grandellis · Earlham Biofoundry Manager Earlham Institute 1
Dr Clive Dix · Chief Executive Officer C4X Discovery 1
Dr Hendrik Waegeman · Head of Business Operations Bio Base Europe Pilot Plant 1
Dr Isabel Webb · Deputy Director for Technology Strategy and Security Department for Science, Innovation and Technology 1
Dr Jim Ajioka · Chief Scientific Officer Colorifix 1
Dr Lucia Marucci · Associate Professor in Systems and Synthetic Biology University of Bristol 1
Dr Martin Turner · Director of Policy and External Affairs Bioindustry Association 1
Dr Mary Maxon · Executive Director BioFutures, Schmidt Sciences 1
Dr Michael Adeogun · Head of Strategy (Life Sciences and Health) National Physical Laboratory 1
Dr Peter Williams · Group Technology Director and Head of Investor Relations INEOS Group Ltd 1
Dr Sara Holland · Patent Attorney Potter Clarkson 1
Fiona Mischel · Director of International Outreach SynBioBeta 1
Graeme Cruickshank · Chief Technology & Innovation Officer Centre for Process Innovation 1
Greg Archer · Director of European Policy LanzaTech UK 1
Justin Tomlinson MP · Minister of State Department for Energy Security and Net Zero 1
Lord Patrick Vallance · Minister for Science, Research and Innovation DSIT 1
Mark Bustard · Chief Executive Officer Industrial Biotechnology Innovation Centre 1
Professor Isabel Oliver · Scientific Officer UK Health Security Agency 1
Professor Nick Talbot · Executive Director and Group Leader The Sainsbury Laboratory 1
Professor Paul Freemont · Co-Director Innovation and Knowledge Centre for Synthetic Biology (SynbiCITE) 1
Professor Robin May · Chief Scientific Adviser Food Standards Agency 1
Professor Susan Rosser · Co-Director Edinburgh Genome Foundry 1
Professor Tom Ellis · Professor of Synthetic Genome Engineering Imperial College London 1
Rosemary Dokos · SVP of Product and Programme Management Oxford Nanopore Technologies 1
The Rt Hon Lord Willetts · Co-founder SynBioVen 1
Will Milligan · Chief Executive Officer Extracellular 1